No Data
No Data
Huachuang Securities: Maintains a "recommended" rating for Hansoh Pharma with a target price of HK$25.44.
Huachuang Securities released a research report stating that it maintains a "recommended" rating for Hansoh Pharma (03692). Profit forecasts adjusted based on the indications of each product and expectations for market launch, with projected revenue for 2024-2026 at 12.155, 12.439, and 14.470 billion yuan respectively; net income attributable to equity holders at 4.259, 3.945, and 4.669 billion yuan, with a target price of 25.44 Hong Kong dollars. The company has basically achieved the transformation into an innovation-driven enterprise, with a record high proportion of revenue from innovative drugs. The R&D pipeline covers a variety of domestic leading varieties, and the international potential of ADC is emerging. Note: The company has achieved
Is IGG Inc's (HKG:799) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
In August, China's gaming market revenue was 33.64 billion yuan, a year-on-year growth of 15.10%.
On September 20, the China Audio and Video Industry Association Game Working Committee released the August 2024 China Game Industry Monthly Report.
IGG: 2024 Interim Report
IGG (00799.HK) repurchased 0.143 million shares for 0.494 million Hong Kong dollars on September 10th.
On September 10th, Gelonghui announced that IGG (00799.HK) repurchased 0.143 million shares for HKD 0.494 million.
Hong Kong stocks: IGG (00799) rose nearly 3% in the afternoon, with strong performance in blockbuster games. The mobile app business may become a new growth driver.
IGG (00799) rose nearly 3% in the afternoon, as of the time of publication, it rose 2.96% to HKD 3.48, with a turnover of HKD 13.3874 million.
No Data
No Data